Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: April 15, 2009
Reporting Period: First Quarter 2009
This filing announces the results of operations for the first quarter of 2009. The detailed financial data is contained in a press release furnished as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the referenced press release (Exhibit 99.1).
The company utilizes non-GAAP financial measures to evaluate ongoing business performance, specifically:
- Net earnings excluding specified items.
- Diluted earnings per common share excluding specified items.
Adjustments are made for unusual or unpredictable factors including acquisition-related costs, cost reduction initiatives, litigation settlements, product launch costs, acquired in-process research and development, and gains/losses on certain investments.
Material Changes
The filing text does not explicitly detail material changes versus the prior comparable period. It directs investors to the press release for the specific results of operations for the first quarter 2009.
Guidance, Outlook, and Management Commentary
Management Commentary: Management believes the presentation of non-GAAP measures provides useful information for evaluating ongoing business performance and is used internally to monitor business performance. However, the company cautions investors to consider these measures in addition to, and not as a substitute for, GAAP financial measures.
Guidance and Risks: The filing text does not contain specific forward-looking guidance, risk factors, or contingencies beyond the standard caution regarding non-GAAP measures.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated April 15, 2009) for specific Q1 2009 revenue, earnings, and cash flow figures.
- Compare GAAP results against the non-GAAP measures provided to understand the impact of one-time items (e.g., litigation, acquisitions).
- Verify the specific adjustments made to net earnings and diluted EPS as defined in the press release.
- Check for any updated full-year guidance included in the referenced press release.